Reuters reports that Pfizer has partially won a patent case against Indian company Ranbaxy in the Netherlands. The win concerns the basic patent over atorvastatin, the active ingredient in Lipitor, and will prevent Ranbaxy from launching a generic version of Lipitor until the atorvastatin patent expires in 2011. Pfizer also lost an invalidity claim concerning the patent salt of atorvastatin.
The IPKat invites his readers to compare the case to the other Lipitor decisions.
The Commission on the Theft of American Intellectual Property Report
-
The Commission on the Theft of American Intellectual Property (The IP
Commission) released its report earlier today, May 22, 2013. The IP
Commission is an...
No comments:
Post a Comment